Nebivolol (versus unexposed)

Study	Type of data	Exposure measurement	Outcome assessment	Adjustment
Delteil, 2024	retrospective cohort (claims database)	Women's drug exposure during pregnancy was estimated on the basis of dispensed prescription drugs recorded by the French Assurance Maladie.	Pregnancy outcomes were obtained from compulsory health certificates at 8 days, 9 months and 2 years for children recorded by the Protection Maternelle et Infantile (PMI) for births, and from data from the Primary Health Insurance Fund and the Toulouse University Hospital.	For malformations: adjusted for folic acid intake, the number of other medications during pregnancy, exposure to at least one teratogenic drug, diabetes and maternal age. SGA adjusted for maternal age, the number of other medications during pregnancy, diabetes and child sex.